Salarius Pharmaceuticals Inc expected to post a loss of $1.30 a share - Earnings Preview

Decoy Therapeutics

02/08/2023 03:02

* Salarius Pharmaceuticals Inc  SLRX.OQ   SLRX.O  is
expected
to show no change in quarterly revenue when it reports 
results on August 3 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Salarius
Pharmaceuticals
Inc is for a loss of $1.30 per share. 
    * The one available analyst rating on the shares is "strong
buy".  
    * The mean earnings estimate of analysts had risen by
about 3.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $8​, above​ its last closing price
of $0.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -2.49       -2.50      -2.23     Beat    10.8
 Dec. 31 2023              -2.15      -2.83     Missed  -31.3
 Sep. 30 2022  -2.62       -2.55      -2.47     Beat    3.1​
 Jun. 30 2022  -2.64       -2.62      -2.25     Beat    14.3
 ​​Mar.        -2.25       -2.25      -3.25     Missed  -44.4
 31 2022                                                
 Dec. 31 2021              -2.12      -2.25     Missed  -5.9​
 Sep. 30 2021  -1.63       -1.62      -2.00     Missed  -23.1
 Jun. 30 2021  -1.50       -1.42      -1.75     Missed  -23.5
 This summary was machine generated August 2 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated